Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 139

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 18
Chunk 139
---
 all of the following are demonstrated:   
●   the technical feasibility of completing the intangible asset so that it will be available for use or sale;
--------------------------------------------------------------------------------------------------------------

●   the intention to complete the intangible asset and use or sell it;
----------------------------------------------------------------------

●   the ability to use or sell the intangible asset;
----------------------------------------------------

●   how the intangible asset will generate probable future economic benefits;
-----------------------------------------------------------------------------

●   the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
--------------------------------------------------------------------------------------------------------------------------------------------------

●   the ability to measure reliably the expenditure attributable to the intangible asset during its development.
----------------------------------------------------------------------------------------------------------------
   Internally-generated intangible assets (capitalised development costs) are stated at cost less accumulated amortisation and impairment, and are amortised on a straight-line basis over their useful lives over a maximum of five years.   As of June 30, 2025, 2024 and 2023, the Group had no capitalized research and development costs. 
(i) Foreign Currency Transactions and Balances
   Functional and Presentation Currency
   The consolidated financial statements are presented in Australian dollars ($), which is Alterity Therapeutics Limited’s functional and presentation currency.   Foreign currency transactions
   All foreign currency transactions during the financial year are brought to account using the exchange rate in effect at the date of the transaction. Foreign currency monetary items at each reporting date are translated at the exchange rate existing at each reporting date. Non-monetary assets and liabilities carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.   Exchange differences are recognised in profit or loss in the period in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned or likely to occur, which form part of the net investment in a foreign operation, are recognised in the foreign currency translation reserve and recognised in profit or loss on disposal of the net investment.
F-15

ALTERITY THERAPEUTICS LIMITED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – in Australian dollars (unless otherwise noted)

1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)

(i) Foreign Currency Transactions and Balances (continued)

Subsidiaries
   The results and financial position of all the Group’s entities that have a functional currency difference from the presentation currency are translated into the presentation currency as follows:   
●   assets and liabilities for each